All In Biotech

Drug Trial Radar · NCT03941262

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Phase 1, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, Autologous Natural Killer Cells in Patients With Pathologically Confirmed Cancer Refractory to Conventional Therapy

Last checked: Nov 19, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Jul 15, 2019

Primary completion

Feb 17, 2023

Study completion Feb 17, 2023

Sponsor

Lead sponsor
NKGen Biotech, Inc.Industry
Sponsor type
Industry
First posted
May 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent and in combination with avelumab or pembrolizumab, for the treatment of subjects with advanced and/or metastatic refractory cancer that has failed three or more prior lines of conventional standard of care therapy.

Conditions

  • Refractory Cancer
  • Metastatic Cancer
  • Recurrent Cancer
  • Unresectable Carcinoma
  • Solid Tumor, Adult
  • Advanced Cancer
  • Advanced Solid Tumor

Interventions

  • SNK01Biological

    Patient-specific ex vivo expanded autologous natural killer cells

  • AvelumabDrug

    Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1).

  • PembrolizumabDrug

    Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety profileTime frame: Up to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sarcoma Oncology Research Center

    Santa Monica, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.